Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite aggressive multimodality therapy, median survival is dismal at 15-16 months from diagnosis, 1 with an urgent need for novel therapeutic approaches. We have previously demonstrated the efficacy of measles virus (MV) 
Edmonston vaccine (MV-Edm) lineage, including derivatives engineered to express the human carcinoembryonic antigen (MV-CEA) and the sodium-iodide symporter gene (MV-NIS) against orthotopic primary patient derived GBM xenografts. [2] [3] [4] [5] [6] In addition, we have retargeted MV against GBM by redirecting viral entry via epidermal growth factor receptor (EGFR) (MV-EGFR), 7 EGFVR variant III (MV-EGFRvIII), 4 and interleukin (IL)-13Rα2 3 receptor, thus increasing the specificity of MV infection. These results were translated into an ongoing phase I clinical trial for recurrent GBM patients.
MV is a single-stranded, negative-sense, enveloped RNA paramyxovirus. The viral genome has 6 genes encoding 8 proteins. 8 The MV hemagglutinin protein mediates viral attachment to its 3 known receptors, CD46, 9 signaling lymphocytic activation molecule (SLAM), 10 and nectin-4. 11 Wild-type MV primarily enters cells through the SLAM receptor, whereas the serially passaged MV-Edm vaccine strains primarily enter cells through the CD46 receptor 8, 11 ; CD46 is ubiquitously expressed on nucleated primate cells and overexpressed in tumors, including GBM. 8 The third MV receptor, nectin-4, is expressed in the respiratory epithelium 11 but also in ovarian, breast, and lung cancers, [12] [13] [14] as well as GBM. 15 Overexpression of MV receptors in human cancers allows for preferential attachment, entry, and selectivity of MV-Edm strains for cancer therapy.
GBM tumors are highly immunosuppressive, including increased levels of programmed cell death ligand 1 (PD-L1) expression, 16, 17 regulatory T cells (T regs ), accumulation 18 monocyte co-option, 19 PD-L1 upregulation on tumor associated macrophage, 17, 19 and systemic immune suppression 20 ; resulting in tumor growth and immune evasion. Cancer therapy with functional blocking antibodies against programmed cell death protein 1 (PD-1) or PD-L1 can restore effector T-cell proliferation and antitumor activity. Two different anti-PD-1 (aPD-1) antibodies-nivolumab (Opdivo) and pembrolizumab (Keytruda)-have been FDA approved for the treatment of melanoma, lung cancer, and renal cell carcinoma. Clinical trials with aPD-1 or anti-PD-L1 antibodies in newly diagnosed or recurrent GBM are ongoing or nearing completion.
Oncolytic viral (OV) infection of tumor cells can initiate antitumor immune responses from the production of pathogen associated chemokines and cytokines, and release of damage-associated molecular pattern (DAMP) [21] [22] [23] [24] [25] [26] molecules and tumor-associated antigens. 27 Supporting the above, in a recently reported clinical trial of measles virotherapy in ovarian cancer, MV therapy was associated with prolongation of survival and induced a type 1 T helper cell (Th1) immune response against tumor-specific antigens, suggesting that the antitumor effect was in part immune mediated. 28 We therefore hypothesized that MV therapy in combination with aPD-1 checkpoint inhibition could significantly complement each other's activity in GBM treatment. Herein we show that MV infection of primary patient GBM cells results in in vitro production and release of DAMPs such as high-mobility group protein 1 (HMGB1) and heat shock protein 90 (HSP90), potentially setting the stage for a pro-inflammatory response in vivo. Upon treatment of mice bearing orthotopic GL261 gliomas with MV-EGFR+aPD-1, there was significant prolongation of survival compared with singleagent therapy, a benefit lost in athymic mice. Mice treated with MV-EGFR+aPD-1 had increased CD8+ T-cell influx into their brains by MRI and fluorescence activated cell sorting (FACS) analysis. Collectively these data can have significant translational implications in GBM treatment.
Materials and Methods

Cell Culture
GL261 murine glioma cells, murine BV2 microglia cells (BV2) (a gift from the Godbout Lab, The Ohio State University), were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum with Pen-Strep (10F DMEM). Primary patient derived glioblastoma lines GBM39, GBM12, GBM10, GBM76, and GBM14 were generated from glioblastoma patients under a Mayo Clinic institutional review board approved protocol and maintained as subcutaneous xenografts and short-term in vitro cultures as previously described. 29 Viruses MV-EGFR, MV-EGFRvIII, MV-NIS, and MV-green fluorescent protein (GFP) were constructed as previously descri bed. 4, 7, 30, 31 
Assessment of MV Titers
This was performed as previously described 2 Coculture Assays for Quantitative Real-Time PCR GL261 cells were plated (7.5 × 10 5 /well) in 2F DMEM and infected with MV-EGFR (MOI = 3) or left uninfected. Coculture assays were then performed with BV2 cells as previously reported. 32 Human cocultures were treated with aPD-1 (1 µg/mL; eBioscience #16-9989-38) or immunoglobulin (Ig)G1-κ (20 µg/mL; Sigma #15154-1146) or left untreated (n = 2 wells/group). RNA was isolated, cDNA synthesis performed, and quantitative real-time (qRT)-PCR conducted using the primers indicated (Supplementary Table 2 ).
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Western Blot for High-Mobility Group Protein 1 and Heat Shock Protein 90 GBM39 and GBM12 cells were plated (2.5 × 10 5 cells) in 1F DMEM, and infected with UV light inactivated MV-NIS (UV-MV-NIS) or MV-NIS (MOI = 0.5) or left untreated. At time points indicated, cell medium (CM) was removed and the cells lysed in Triton lysis buffer. Equal amounts were run for western blot, and proteins of interest were probed for, as previously described. 22 Western blot antibodies used are detailed in the Supplementary material.
Transwell Assays
Transwell assays were performed using MV infected GL261 cells. BV2 cells were harvested and added to the transwell inserts. aPD-1 (1 µg/mL), IgG1-κ (20 µg/mL), and concentrated conditioned CM (derived from infected and uninfected respective cells and concentrated in Millipore [centrifuge filters #UFC90324]) was added. Inserts were then stained with 4′,6′-diamidino-2-phenylindole, and the average number of migrated monocytes enumerated. Additional information is provided in the Supplementary material.
Animal Experiments
All animal experiments were approved by the Mayo Institutional Animal Care and Use Committee. Orthotopic tumors were established by implantation of 3 × 10 5 GL261 cells, [2] [3] [4] [5] [6] into the caudate nucleus, using a small animal stereotactic frame (ASI Instruments) and a 26-gauge Hamilton syringe. Athymic nu/nu mice were obtained from Harlan and C57BL/6 mice from Charles River Laboratories. MV-EGFR or UV-MV-EGFR was administered at 2 × 10 5 per median tissue culture infectious dose (TCID 50 ) intratumorally using the same coordinates as for cell implantation. Murine aPD-1 (200 µg/mouse) (BioLegend #114110) was administered i.p.
Ex vivo Fluorescence Activated Cell Sorting Analysis
Mice were treated as previously described under "Animal Experiments. " On day 11 post tumor implantation, mice were euthanized, their brains removed, cerebellums discarded, and lymphocytes isolated from the rest of the brain. The list of fluorochrome conjugated antibodies used in FACS analysis is provided in the Supplementary material.
MRI for Detection of Inflammatory Cells and T Cells
All MR imaging was performed on a Bruker Ultrashield 300 MHz (7T) vertical bore nuclear MR spectrometer equipped with "mini-imaging" accessories as previously described. 33 
Detection of Tumor Monocytic Infiltration by MRI
GL261 tumor cells were implanted orthotopically into C57BL/6 mice as described in "Animal Experiments. " Seven days later, the mice were injected with MV-EGFR or UV-MV-EGFR (2 × 10 5 TCID 50 , 10μL) or were left untreated. In order to visualize inflammatory cells, mice received tail vein injections of 100 μL of FeraSpin particles (Miltenyi #130-095-171) and underwent T2 MRI (spoiled gradient echo: 7ms, rep: 50ms, excitation [length: 1ms, flip angle: 40degrees, atten: 12.7 dB]) daily for 3 days following MV therapy.
Detection of T Cells by MRI
In a separate experiment, mice bearing syngeneic orthotopic GL261 glioma xenografts were treated as described under "Animal Experiments. " On day 10 post tumor implantation, all mice received labeled CD4 (#130-049-201) and CD8a (#130-049-401) microbeads (Miltenyi) via tail vein as previously described. 33 The following day, the mice underwent T2* MRI (spoiled gradient echo: 2ms, rep: 
Statistical Analysis
Kaplan-Meier survival curves were used to assess animal survival, and comparisons were performed using the logrank test. ANOVA with a post-hoc Tukey test was employed to analyze FACS and MRI data. All other assays used Student's t-test for analysis. P < .05 was considered statistically significant.
Results
Variable Upregulation of Programmed Cell Death Ligand 1 and Human Leukocyte Antigen-ABC upon Interferon-γ Stimulation of GBM Cells
MV infection has been shown to elicit an immune mediated IFN-γ response. 34 Previous reports have shown that IFN-γ stimulation of tumor cells can result in increased expression of immunomodulatory molecules such as PD-L1, human leukocyte antigen (HLA)-ABC, and/or HLA-G. We therefore examined the expression changes of these molecules in primary patient derived GBM lines and murine GBM lines following IFN-γ treatment. We demonstrated that PD-L1 expression is upregulated in the human GBM cell lines GBM 39 and GBM12 at 24 and 36 hours post IFN-γ treatment (Fig. 1A-1D) . Additionally, the murine GL261 glioma cell line constitutively expressed high levels of PD-L1, which was only modestly increased following IFN-γ treatment (Fig. 1E-1F ). IFN-γ treatment had a variable impact on expression of HLA-ABC molecules, with upregulation being observed in 2 of 5 primary GBM lines tested (Supplementary Fig. 1 and Supplementary Table 1) . Upregulation of the immune inhibitory molecule HLA-G was observed in only 1 of 5 primary GBM lines.
Early MV Infection of GBM Cells Upregulates Molecules Involved in Immune Evasion Pathways
We next assessed the effect that MV infection of GBM cells has on PD-L1 expression in vitro. Human GBM cells were infected with MV-NIS, an oncolytic MV strain currently in clinical testing. UV-inactivated MV-NIS treated cells and untreated cells were used as controls. Murine GL261 cells are not infectable with MV-NIS due to lack of expression of natural MV receptors in rodent lines, and thus they were infected with the retargeted strain MV-EGFR. Analysis by flow cytometry following 24-and 36-hour incubation showed that MV-NIS infection increased PD-L1 expression on both human cell lines by 36 hours (Fig. 1A-1D ). GL261 
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cells continued to express high levels of PD-L1 regardless of treatment ( Fig. 1E-1F) . Consistent with the IFN-γ treatment results, we observed only modest differences in major histocompatibility complex I expression (human HLA-ABC or murine H2-K b ) in MV infected cells (Supplementary Fig. 1 ). Likewise, we saw minimal differences in human HLA-G or murine Qa-2 expression (Supplementary Fig. 1 ). Together, these data indicate that the inflammatory environment mediated by MV infection promotes PD-L1 expression in human GBM. Additionally, high expression of PD-L1 by the GL261 glioma cell line suggests that aPD-1 could have therapeutic utility in combination with MV therapy.
MV Infection of Human GBM Cells Can Result in High-Mobility Group Protein 1 and Heat Shock Protein 90 Production
Oncolytic virus infection of tumor cells has been shown to result in the production of DAMPs, including HMGB1 and HSP90, which can augment an immune response. [21] [22] [23] [24] [25] [26] 35 We therefore examined MV infected primary patient GBM12 and GBM39 lines for DAMP production. CM and cell lysate from treated cells were probed by western immunoblotting for the indicated proteins (Fig. 1G, 1H ). MV infection resulted in a significant increase in the production of the pro-inflammatory mediator HMGB1 at 48 hours post MV infection in both primary GBM cell lines (Fig. 1G) . Increased production of secreted HSP90 was also observed following infection of primary GBM12, but not GBM39 cells (Fig. 1H) .
Murine GL261 Glioma Cells Can Be Infected by MV-EGFR but Infection Is Nonproductive
The assessment of MV+aPD-1 activity in vivo required testing in an immunocompetent syngeneic murine model. Murine cells do not express the natural MV receptors CD46, nectin-4, or SLAM to allow for MV infection. 36, 37 To circumvent this barrier, we used retargeted MV that infects murine cells via alternative receptors. Prior to initiation of in vivo studies, we sought to determine whether GL261 glioma cells were infectable by retargeted MV strains. Briefly, the EGFR-expressing 38 GL261 cells were infected with MV-GFP, MV-EGFR, MV-EGFRvIII (MOI = 3) or UV-inactivated MV strains. The MV-EGFR and MV-EGFRvIII strains also encode GFP. Following infection, MV-produced GFP expression was assessed by FACS ( Fig. 2A) and fluorescent microscopy (Fig. 2B) to confirm infection. Vero cells infected with MV-GFP (MOI = 1) for 24 hours were used as a positive control. Results showed GFP production in GL261 cells infected at low levels by MV-EGFR. These results were confirmed and quantified by FACS, showing that an MOI = 3 yields approximately 15% infection.
MV-EGFR Infection of Murine GL261 Glioma Cells Significantly Increases Pro-Inflammatory and ProMigratory Responses of BV2
Microglia are resident monocytes of the central nervous system. 39 BV2 microglia are immortalized microglia isolated from C57BL/6 mice and represent an alternative model system to primary microglia. 40, 41 Using BV2, we analyzed the effects of MV-EGFR infection of murine GL261 GBM cells (Fig. 2C ) in coculture. Quantitative RT-PCR for pro-inflammatory gene expression showed significant increase in mRNA levels for IFN-α, IFN-β, and IFN-γ in cocultures of BV2+MV-EGFR+GL261 cells compared with uninfected cocultures (P<.05; Fig. 2C ). These results indicate that MV-EGFR infection of GL261 cells is capable of stimulating a pro-inflammatory response in murine microglia.
Transwell assays were used to assess whether MV-EGFR infection of GL261 cells could increase BV2 migratory response. MV infection of GL261 cells significantly increased the pro-migratory response of BV2 microglia compared with uninfected GL261 cells (P = .039; Fig. 2D ).
MV-EGFR Therapy of Mice Bearing Orthotopic GL261 Gliomas Elicits a Pro-Inflammatory Response as Assessed by Monocyte MION MRI Analysis
We next sought to determine whether MV-EGFR therapy of mice bearing syngeneic orthotopic GL261 gliomas elicits a pro-inflammatory response. For this we employed monocyte MRI analysis using MION as previously described. 42 Seven days post tumor implantation the mice received a single intratumoral dose of UV-MV-EGR or MV-EGFR (2 × 10 5 TCID 50 ) or were left untreated (n = 3/group). T2 weighted MRI obtained at 24 hours post MV therapy (Fig. 2E) showed increased influx of monocytes into the brains of mice treated with MV-EGFR compared with the other therapy groups. Figure 2F is a representative reconstruction of day 1 MRI (red shading = MION positive areas). These results combined with the results of the BV2 assays indicate that treatment of GL261 gliomas with MV-EGFR results in a monocyte inflammatory response in vivo; this inflammatory response sharply decreases after day 1 in vivo, possibly as a result of the limited ability of the MV-EGFR virus to replicate in murine lines, including GL261.
MV-EGFR Therapy in Combination with aPD-1 Blockade Therapy Significantly Enhances Survival of Mice Bearing Syngeneic Orthotopic GL261 Gliomas
Following in vitro evidence of MV-EGFR infection of GL261, we employed the orthotopic GL261 tumor model in order to assess the in vivo efficacy of MV+aPD-1 therapy. C57BL/6 mice bearing orthotopic GL261 gliomas were treated as outlined in "Materials and Methods" following the timeline shown in Fig. 3A . Mice which received MV-EGFR+aPD-1 had a significant enhancement of survival compared with the other therapy groups (vs untreated [P = .0039], vs MV-EGFR [P = .0097], vs aPD-1 [P = .0387]) (Fig. 3A) . Sixty percent of the mice were deemed long-term survivors, remaining alive for at least 120 days.
Mice that received the aPD-1 monotherapy regimen had significant survival enhancement compared with untreated mice (P = .0039) but not compared with MV-EGFR therapy regimen treated mice (P = .0636). There was no significant enhancement of survival for mice treated with the MV-EGFR therapy regimen alone compared with untreated mice (P = .1283). Treatment with aPD-1 was well tolerated in this model, with no systemic or neurologic toxicity being observed.
MV-EGFR+aPD-1 Therapy of Mice Bearing Syngeneic Orthotopic GL261 Glioma Increases Tumor T-Cell Influx as Assessed by T2* MRI
Next we sought to determine whether the significantly enhanced survival observed in the MV-EGFR+aPD-1 group was due to an immune effect. In a parallel experiment using the same GL261 efficacy model, mice were treated as shown in the Fig. 3B timeline. Mice received a tail vein injection of CD4 and CD8 antibody conjugated ultrasmall superparamagnetic iron oxide particles (USPIO) using a previously established protocol 33 ; quantification of the USPIO-positive area from T2* MRI on day 11 post tumor implantation showed that mice receiving MV-EGFR+aPD-1 had a larger influx of T cells into their brains compared with all other therapy groups. Representative reconstructions of scans shown (Fig. 3C) visually illustrate this effect. These T2* MRI results support a T-cell mediated immune response in the MV-EGFR+aPD-1 therapy treated group.
Mice Bearing Orthotopic GL261 Tumors Treated with MV-EGFR+aPD1 Have an Increased Influx of Granzyme B+ CD8+ T Cells
In a separate experiment, C57BL/6 mice bearing GL261 orthotopic tumors were treated according to the Fig. 3A timeline. Lymphocytes isolated from the brain of GL261 bearing mice were analyzed via flow cytometry at 11 days 
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post tumor implantation, the same time point assessed via T2* MRI in Fig. 3 . Flow cytometry analysis demonstrated increased influx of T cells (CD3+ CD45.2hi) into the brains of mice treated with MV-EGFR+aPD-1 (Fig. 4A, 4B) . Further characterization of the T-cell subpopulations revealed that mice treated with MV-EGFR+aPD-1 had a higher percentage of CD8+ T cells (Fig. 4C) , an increased percentage of CD8+GzmB+ T cells (Fig. 4D) , as well as an increase in the CD8+ T cell:T reg ratio (Fig. 4E ) compared with no treatment, treatment with UV-inactivated virus, or monotherapy. Examination of total CD4+ T cells, as well as the T reg (CD3+ CD45.2hi+ FoxP3+) or conventional T cell (CD3 +CD445.2hi CD4+ FoxP3−) subpopulations demonstrated no significant difference between treatment groups (data not shown).
Enhanced Survival Observed with MV-EGFR+aPD-1 Is Dependent on T-Cell Mediated Responses
To further investigate whether a T-cell mediated response is required for the observed enhanced survival in the MV-EGFR+aPD-1 therapy group (Fig. 3A) , we established GL261 gliomas by implanting 3 × 10 5 cells orthotopically in the caudate nucleus of athymic nude mice. The mice received the same therapy regimen that was used in the GL261, C57BL/6 model (n = 5/group). Survival analysis showed loss of survival enhancement for the MV-EGFR+aPD-1 treatment group compared with untreated mice (P = .2143) (Fig. 5) . Furthermore, there was no difference in survival between untreated and aPD-1 treated mice (P = .1311). This supports the requirement of a T-cell mediated response for the observed increase in survival for both the aPD-1 and the MV-EGFR+aPD-1 combination therapy in the C57BL/6 GL261 orthotopic model.
Discussion
In this manuscript we demonstrate for the first time that oncolytic (MV platform based) virotherapy has synergistic activity with aPD-1 therapy in GBM treatment. These data complement previous reports in B16 melanoma, using Reovirus, 43 or MV engineered to express anti-CTLA4 or anti-PD-L1 antibodies. 44 Oncolytic virotherapy of cancer has shown preclinical promise and it is currently being clinically evaluated in GBM treatment. 45, 46 OV infection of tumor cells has also been shown to initiate systemic antitumor/antiviral immune responses. 22, 23, 25, 26, 35 There is accumulating evidence that MV infection has immunostimulatory properties. Donnelly and colleagues showed that MV infection of human melanoma cell lines induced a dose-dependent increase in IL-6 and IL-8, as well as variable increase in IFN-α, IFN-β, and IFN-λ. 22 Moreover, MV infection in melanoma led to dendritic cell activation stimulating a CD8+ cytotoxic T-cell response. In clinical trials, MV treatment of ovarian cancer patients generated a tumor-specific Th1 response. 28 Findings presented in this manuscript support the immunostimulatory potential of MV infection against GBM.
GBM tumors are immunosuppressive, 17, 19, 47 and reversal of this status-for example, by using immune checkpoint blockade-could lead to improvement in outcome. A number of clinical trials for newly diagnosed or recurrent GBM patients using aPD-1 or anti-PDL-1 antibodies are currently ongoing or soon to be activated, while combinatorial strategies are also evolving. In this manuscript, we showed that combined oncolytic MV therapy and aPD-1 therapy significantly increases antitumor activity in immunocompetent mice compared with single-agent aPD-1 treatment. In in vitro work, we demonstrated that MV infection of GBM lines resulted in an initial increase of the immune evasion molecule PD-L1, supporting the rationale of a combinatorial strategy with aPD-1 or PD-L1 blockade. As the MV infection progresses, infected GBM cells produce and release different DAMP molecules, such as HMGB1 and less consistently HSP90. HMGB1 production and release by OV has been shown to be associated with immune mediated tumor clearance, 48 including in the CNS1 rat GBM model. 21 In vivo, MV+aPD-1 therapy significantly increased the survival of mice bearing orthotopic GL261 GBM compared with single-agent therapies. The constitutive high PD-L1 expression in GL261 cells could represent an important determinant of the efficacy of this immunovirotherapy strategy, even in the context of limited replication of MV strains in murine lines. Ongoing experiments using murine glioma lines (such as the DBT glioma line) with lower PD-L1 expression will allow us to test this hypothesis. 
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It should be noted that the viral dose of 2 × 10 5 TCID 50 used in our experiments is equivalent to approximately 10 8 TCID 50 in humans (using the FDA commonly recommended brain weight conversion method) and thus it could be directly translatable to a dose level that would be easy to manufacture and administer in a clinical trial. MRI following tail vein administration of CD4 and CD8 antibody conjugated USPIO demonstrated increased proportion of brain infiltrating T cells in mice receiving combination MV-EGFR+aPD-1 therapy compared with all other treatment groups. Further supporting these data, FACS analysis of mouse brains confirmed increased CD8+ T-cell influx into the brains of mice receiving MV-EGFR+aPD-1 therapy compared with the other therapy groups. The requirement of a T-cell mediated response for enhanced survival in the MV-EGFR+aPD-1 therapy group is further supported by the survival analysis of athymic nude mice bearing GL261 orthotopic tumors; there was no significant enhancement of survival for either the MV-EGFR+aPD-1 therapy group or the aPD-1 therapy group compared with the other therapy groups. Of note, aPD-1 does not affect MV replication in infected GBM cells (Supplementary Fig. 3 ).
In in vitro experiments, we demonstrated that MV infection of murine GL261 cells evoked a microglial pro-migratory response in transwell assays. Additionally, qRT-PCR for pro-inflammatory cytokine genes showed that MV infection of GBM cells evoked a pro-inflammatory response from BV2 microglia in coculture. The limited MV-EGFR replication in the GL261 model resulted in a self-limited surge of inflammatory phagocytic cells at 24 hours following viral administration, and thus it does not allow us to conclusively address the role of macrophages in our MV/aPD-1 therapy model. The loss of antitumor activity of this combination regimen in an immunocompromised nude mouse GL261 model (which still has macrophages), 49 however, suggests that macrophages are unlikely to represent a major determinant of the observed antitumor response in this model. Similar to our results indicating the requirement of a T-cell mediated response for enhanced survival for MV+aPD-1 therapy of GL261 GBM, Rajani et al 43 combined Reovirus+aPD-1 for the treatment of B16 melanoma and found that a CD8+ T-cell mediated response was in part required for the observed enhanced therapeutic efficacy. Additionally, Cockle et al 50 reported on an immunotherapy approach using vaccination with vesicular stomatitis virus (VSV) constructs expressing glioma antigens +aPD-1 therapy for treatment of GL261 gliomas; the observed efficacy in the combination VSV+aPD-1 treatment group was found to be mediated by an IFN-γ driven Th1 response.
This manuscript is the first report demonstrating that combining the activity of oncolytic virotherapy (using a retargeted MV) with aPD-1 blockade results in significant enhancement of survival in a syngeneic orthotopic GBM model. Despite limited MV replication in the GL261 cells, we demonstrated that MV therapy can stimulate a self-limited pro-inflammatory response, which could be effectively augmented by aPD-1 therapy in vivo, resulting in significantly increased animal cure rate via a CD8+ T cell mechanism. While additional mechanistic studies are ongoing, we believe these data support the potential of clinical strategies combining oncolytic virotherapy with aPD-1 therapy for GBM treatment.
Supplementary Material
Supplementary material is available at Neuro-Oncology online.
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